CHRS Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own CHRS shares is 173, representing 69.5% of the company's common stock.

STATE STREET CORP, in the last quarter, reduced its stake in CHRS by -3.32% restricting it's holding to 2 million shares of worth nearly $4.77M. MILLENNIUM MANAGEMENT LLC also lessened -55.76% of the CHRS shares from its portfolio, reducing its holding to 1.26 million shares of worth $3.01M. PEREGRINE CAPITAL MANAGEMENT LLC also shunned CHRS shares holding by -6.74% last quarter which brought its holding to 1.02 million shares worth $2.43M.

As per its latest 13F filing, CITADEL ADVISORS LLC increased its stake in CHRS by 37.97% in the last quarter. The institutional holder raised its holding to 2.74 million shares having worth more than $6.55M. MORGAN STANLEY also added 28.71% more shares of CHRS to its portfolio, raising its holding to 2.66 million shares of worth $6.37M. BANK OF AMERICA CORP /DE/ also increased its CHRS shares holding by 14.56% which brought its holding to 2.43 million shares worth $5.80M.

The insider with the most stakes in CHRS is Lanfear Dennis M , President & CEO at the company. Additionally, CHRS stock is highly held by Chief Financial Officer Viret Jean-Frederic and Chief Operating Officer Anicetti Vincent R among others.

Company executives, directors, and other insiders own 1.38% percent of Coherus BioSciences, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which CHRS insiders have sold stock, totaling 0 shares. Insiders that have sold shares include LANFEAR DENNIS M, STILWELL MCDAVID, and HEALY JAMES.

There have been 0 transaction(s) during the past 6-months in which Coherus BioSciences, Inc. insiders have bought stock, totalling 0 shares

Around 0 Coherus BioSciences, Inc. shares are held by insiders, which represents about 1.38% of CHRS stock.

CHRS President & CEO, Lanfear Dennis M holds the largest portfolio of the company's shares. CHRS shares owned by Lanfear total nearly 731.69 thousand.

STATE STREET CORP is the largest institutional owner in CHRS which holds 2 million shares worth $4.77M or 2.12% of the total CHRS shares outstanding followed by KOHLBERG KRAVIS ROBERTS & CO. L.P. with ownership of 3.04 million shares representing 3.22% of the CHRS ownership. CITADEL ADVISORS LLC is the third largest stakeholder with 2.74 million shares or 2.91% of the ownership worth more than $6.55M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the CHRS is concerned, it is a stock which is optionable.

Number of CHRS shares short is 30.72M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 115.21M shares of CHRS are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, CHRS has 103.30M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for CHRS is 3.38.